{
    "name": "raloxifene",
    "comment": "Rx",
    "other_names": [
        "Evista"
    ],
    "classes": [
        "Selective Estrogen Receptor Modulators"
    ],
    "source": "https://reference.medscape.com/drug/evista-raloxifene-342794",
    "pregnancy": {
        "common": [
            "Pregnancy Category: X",
            "Lactation: Excretion in milk unknown; contraindicated"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in milk unknown; contraindicated"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Increased risk of deep vein thrombosis and pulmonary embolism has been reported with this drug",
                "Women with active or past history of venous thromboembolism should not take this drug",
                "Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events",
                "Consider risk-benefit balance in women at risk for stroke"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy, lactation",
                "Active history of thromboembolic disorders",
                "Women who could become pregnant"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinue 72 hours prior to and during prolonged immobilization",
                "Associated with increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis",
                "Increased risk of death due to stroke; consider risk-benefit balance in women at risk for stroke",
                "Supplemental calcium and vitamin D recommended",
                "Therapy should not be used for primary or secondary prevention of cardiovascular disease",
                "Triglyceride levels may increase in women with history of triglyceride elevation in response to oral estrogens; monitor serum triglycerides",
                "Concomitant use of estrogens not recommended; taper off estrogen treatment, then wait month before starting raloxifene",
                "Examine unexplained uterine bleeding",
                "Use with caution in renal or hepatic impairment",
                "Premenopausal use not recommended"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ospemifene",
            "description": {
                "common": "ospemifene, raloxifene.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of raloxifene by  increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and may decrease systemic exposure of drugs that are UGT substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of raloxifene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "famciclovir",
            "description": {
                "common": "raloxifene decreases levels of famciclovir by aldehyde dehydrogenase inhibition. Use Caution/Monitor. The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase. Interactions with other drugs metabolized by this enzyme and/or inhibiting this enzyme could potentially occur. Raloxifene, a potent aldehyde oxidase inhibitor in vitro, could decrease the formation of penciclovir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "raloxifene decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hot flashes",
            "percent": "8-29"
        },
        {
            "name": "Flu syndrome",
            "percent": "14-15"
        },
        {
            "name": "Cramps",
            "percent": "6-12"
        },
        {
            "name": "muscle spasm",
            "percent": "11-16"
        },
        {
            "name": "Arthralgia",
            "percent": "11"
        },
        {
            "name": "Infection",
            "percent": "6"
        },
        {
            "name": "Insomnia",
            "percent": "5"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Sinusitis",
            "percent": "1-2"
        },
        {
            "name": "Venous thromboembolism",
            "percent": "10"
        },
        {
            "name": "Bronchitis",
            "percent": "8"
        },
        {
            "name": "Pharyngitis",
            "percent": "4"
        },
        {
            "name": "Breast pain",
            "percent": "3"
        },
        {
            "name": "Gastroenteritis",
            "percent": "3"
        },
        {
            "name": "Diaphoresis",
            "percent": null
        },
        {
            "name": "Deep vein thrombosis",
            "percent": null
        },
        {
            "name": "Cerebrovascular accident",
            "percent": null
        },
        {
            "name": "Thrombosis of retinal vein",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Pulmonary embolism",
            "percent": null
        },
        {
            "name": "Decreased fibrinogen",
            "percent": null
        }
    ]
}